Navigation Links
TGen breast cancer research benefits from $3.5 million Komen award
Date:9/23/2011

tients with triple-negative breast cancer so often fail to respond to available therapies, and to design new ways to more effectively treat this difficult form of cancer."

Dr. Wicha, M.D., Distinguished Professor of Oncology and Director of the U-M Comprehensive Cancer Center, was one of the first to identify cancer "stem cells" in solid tumors, recognizing them in breast cancer tissue in 2003. Cancer stem cells are the small number of cells within a tumor that continually fuel the tumor's growth and spread, rendering the tumor resistent to today's therapies. Many researchers believe traditional chemotherapy and radiation treatments often become ineffective because they do not kill the cancer stem cells, and that the key to future treatments is to develop drugs that target and kill these cells. Research suggests that triple-negative breast cancers have a higher proportion of cancer stem cells.

Among women with breast cancer, triple negative breast cancer represents about 15 percent of diagnoses in Caucasian American women, but 26 percent in African American women and up to 82 percent in west African women. The grant proposal includes studying tumor cells from African and African-American women to look for molecular differences in triple-negative tumors. Laboratory research will look at whether targeting the breast cancer stem cells has an impact on these tumors.

"Through this research study, we will be able to provide key insights into whether or not cancer stem cells plays a role in the significant differences observed in death rates among women of west African origin who are more likely to be diagnosed with, and die from, this terrible form of cancer," said Dr. Heather Cunliffe, Head of TGen's Breast & Ovarian Cancer and a co-investigator on the study.

Researchers also plan to launch at least three clinical trials to investigate new treatments that target cancer stem cells. Based on the results of these trials, a larger r
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. The dietary supplement genistein can undermine breast cancer treatment
3. Breast cancer cells recycle to escape death by hormonal therapy
4. Second lumpectomy for breast cancer reduces survival rates
5. Study looks at psychological impact of gene test for breast cancer
6. SNM releases new fact sheet on breast cancer and molecular imaging
7. Study links nicotine with breast cancer growth and spread
8. UC Davis researchers discover a key to aggressive breast cancer
9. CTRC-AACR San Antonio Breast Cancer Symposium
10. Einstein researchers develop a new way to study how breast cancer spreads
11. Mayo researchers identify dangerous two-faced protein crucial to breast cancer spread and growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... expecting a very large "dead zone" in the Gulf ... in the Chesapeake Bay this year, based on several ... of Michigan, Louisiana State University, and the Louisiana ... of Mexico hypoxic "dead" zone will be between 7,286 ... the ten largest recorded. That would range from an ...
(Date:6/18/2013)... awarded $12.7 million to match nine academic research ... to explore new treatments for patients in eight ... and schizophrenia. The collaborative pilot initiative, called Discovering ... by the National Center for Advancing Translational Sciences ... , The process of developing a new therapeutic ...
(Date:6/18/2013)... Bethesda, MD, June 18, 2013: The Association for Molecular ... Federation of American Societies for Experimental Biology (FASEB) on ... for membership on June 3, 2013. , The ... individuals and share a common vision for the advancement ... "Basic biomedical and translational research is more important now ...
Breaking Biology News(10 mins):NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... sites of fundamental geodynamic, geochemical and biological processes and ... for us. Scientific marine drilling and coring is crucial ... (sub-) seafloors to advance our knowledge in the Earth ... (ESF) European Collaborative Research (EUROCORES) programme EuroMARC is an ...
... Calif., November 23, 2008 -- Peregrine Pharmaceuticals, Inc. ... Nature Medicine that supports the broad ... antibody platform, showing that its PS-targeting drug bavituximab ... models. Bavituximab is in clinical ...
... Futronic Technology Company Limited, a,global provider of ... of FS22, a high performance fingerprint access and,attendance ... launched,FS21M (mid-range device) and FS20 (low cost device), ... and attendance control device.,FS22 uses a powerful Digital ...
Cached Biology News:Europe cores in EUROCORES: Ocean drilling in EuroMARC 2Europe cores in EUROCORES: Ocean drilling in EuroMARC 3Europe cores in EUROCORES: Ocean drilling in EuroMARC 4Europe cores in EUROCORES: Ocean drilling in EuroMARC 5Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 2Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 3Futronic Launches FS22 Fingerprint Access Control Device 2
(Date:6/18/2013)... , June 18, 2013  AMRI (NASDAQ: ... Burlington, Mass. , site has received ... Administration (DEA) registration to handle Schedule 2 and ... acknowledgement of Burlington,s physical ... documentation. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ...
(Date:6/18/2013)... ZIONA, Israel , June 18, 2013 ... complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, ... announced today that the company has been granted a ... indicated in the US and Europe ... US Patent number 8,410,176 B2 is titled Intermediate Compounds ...
(Date:6/18/2013)... Canada (PRWEB) June 18, 2013 ... oversight of pharmaceutical advertising and promotion, and review ... Viewers will learn how to apply these principles ... examples:, ,     The fundamentals on FDA ... and promotional labeling ,     Assessing traditional and ...
(Date:6/18/2013)... , June 18, 2013 ... has announced the addition of the ... Microspheres, & Nanoparticles], Devices [Disposables & Reusable, ... Auto Injectors] & Therapeutics [Diabetes & Oncology] ... to their offering.      (Logo: ...
Breaking Biology Technology:AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3
... Novocell, Inc. , a preclinical stage diabetes ... award totaling $20 million from the California Institute for Regenerative ... scientists at the University of California, San Francisco (UCSF), led ... million. The funding will advance Novocell,s development of a first ...
... Nev., Oct. 28 PDL BioPharma, Inc. (PDL) (Nasdaq: ... a $300 million securitization transaction intended to monetize certain ... closing of the transaction, which is expected to occur ... QHP Royalty Sub LLC ("QHP"), a newly-formed wholly-owned subsidiary ...
... Novavax, Inc. (Nasdaq: NVAX ) announced ... joint venture between Cadila Pharmaceuticals in India, has ... will be used to produce pandemic and seasonal ... virus-like particle (VLP) vaccine technology to produce commercial-scale ...
Cached Biology Technology:Novocell Receives a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 2Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 4Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 5
SDS-OutT Precipitation Reagent...
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
Designed for use with the Agencourt SprintPrep 384 kit and all MCPrep reagent kits. Used with flat bottom 96-well microplates such as deep well plates used to culture bacteria....
ID clarifier: non-treated with lid...
Biology Products: